A valuable contribution to dermatology
DermaGen develops novel antimicrobial peptides (AMPs) directed against skin microbes, primarily bacteria. These peptide therapeutics kill microbes by disrupting their membranes, which leads to cell lysis and death.
Read more »
The challenge of multiresistance
Multiresistant bacteria such and MRSA and VRE are causing serous problems within health care. In hospitals they typically give rise to noscomial infections that are difficult to treat with antibiotics.
Read more »
A safe product nearing the market
The AMPs discovered and developed by DermaGen are evaluated extensively through a combination of advanced biophysical methods. Our strategy is to develop AMPs with unique capabilities and antibacterial spectrum.
Read more »
Latest news
02.12.09
Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic
Read more »
06.07.09
DermaGen AB has completed patient enrolment for a Phase I/IIa clinical trial for DPK-060, a novel antimicrobial peptide.
Read more »
13.05.09
DermaGen will attend BIO2009 in Atlanta.
Read more »
Our Company
Foundation
Ownership
Directors
Management
The Challenge
Resistance
Allergenicity
Toxicity
Market potential
Technology
AMPs
Properties
Action
Our AMPs
Our patents
References
Indication
Atopic dermatitis
Potential applications
Product Development
Product candidates
Pipeline
Business model
Partnerships
Licensing
Collaboration
Contacts
We are here
News




© DermaGen 2008
Phn: +46 46 192 197
Fax: +46 46 123 536
E-mail: info@dermagen.se
Orgnr. 556655-4431